|Bid||273.00 x 143000|
|Ask||278.50 x 182300|
|Day's range||273.50 - 278.00|
|52-week range||134.40 - 286.20|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Positive dose-finding results with ACT-132577 - asset to progress to Phase 3 development in resistant hypertension Positive safety study with cenerimod - asset to progress into larger Phase 2 development ...
ALLSCHWIL/BASEL, SWITZERLAND - 15 May 2017 - Actelion Ltd (SIX: ATLN) today announced changes to its executive team that would only take effect upon closing of the transaction with Johnson & Johnson expected ...
Transaction remains on track to close towards the end of the second quarter of 2017 ALLSCHWIL, SWITZERLAND - 27 April 2017 - Actelion Ltd (SIX: ATLN) today announced that Janssen Holding GmbH, a Swiss ...